Valerion Therapeutics, LLC is a provider of bio-therapeutics services that offer an antibody-mediated delivery platform to target specific tissues, enhancing intracellular delivery of active therapeutic payloads via a transport mechanism present in muscle and neurons. The company's demonstrated pre-clinical in vivo data with its two lead product candidates validates the potential of the delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders. This provides clinicians with a novel way to treat a number of diseases with limited or no current therapeutic options.